Bayer AG's corporate venture arm has invested more than €1.3bn since 2015 and intends to match that sum from now through 2024 to support biotechs developing innovative technologies in healthcare.
At the German major's first 'breakthrough innovation forum' on 1 April, outlining the company's long-term plans in pharma and agriculture,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
